Format
Sort by
Items per page

Send to

Choose Destination

Best matches for psoriasis randomized:

Search results

Items: 1 to 20 of 2754

1.

Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks.

von Stebut E, Reich K, Thaçi D, Koenig W, Pinter A, Körber A, Rassaf T, Waisman A, Mani V, Yates D, Frueh J, Sieder C, Melzer N, Mehta NN, Gori T.

J Invest Dermatol. 2018 Nov 30. pii: S0022-202X(18)32904-X. doi: 10.1016/j.jid.2018.10.042. [Epub ahead of print]

PMID:
30508547
2.

Secukinumab for plaque psoriasis.

Ordenes-Cavieres G, Andino-Navarrete R.

Medwave. 2018 Nov 30;18(7):e7364. doi: 10.5867/medwave.2018.07.7363. Spanish, English.

PMID:
30507896
3.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB.

Br J Dermatol. 2018 Nov 28. doi: 10.1111/bjd.17454. [Epub ahead of print]

PMID:
30485400
4.

Severe de novo Ulcerative Colitis following Ixekizumab Therapy.

Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV.

Case Rep Gastroenterol. 2018 Oct 17;12(3):617-621. doi: 10.1159/000493922. eCollection 2018 Sep-Dec.

5.

Online Care versus In-Person Care for Improving Quality of Life in Psoriasis: A Randomized Controlled Equivalency Trial.

Armstrong AW, Ford AR, Chambers CJ, Maverakis E, Dunnick CA, Chren MM, Gelfand JM, Gibbons CM, Gibbons BM, Lane CJ.

J Invest Dermatol. 2018 Nov 24. pii: S0022-202X(18)32831-8. doi: 10.1016/j.jid.2018.09.039. [Epub ahead of print]

PMID:
30481495
6.

Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.

McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF.

Am J Clin Dermatol. 2018 Nov 23. doi: 10.1007/s40257-018-0408-z. [Epub ahead of print]

PMID:
30471012
7.

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.

Al-Salama ZT, Scott LJ.

Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1.

PMID:
30467781
8.

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.

Yosipovitch G, Reich A, Steinhoff M, Beselin A, Kent T, Dossenbach M, Berggren L, Henneges C, Luger T.

Dermatol Ther (Heidelb). 2018 Dec;8(4):621-637. doi: 10.1007/s13555-018-0267-9. Epub 2018 Nov 21. Review.

PMID:
30465321
9.

Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.

Ighani A, Partridge ACR, Shear NH, Lynde C, Gulliver WP, Sibbald C, Fleming P.

J Cutan Med Surg. 2018 Nov 21:1203475418814234. doi: 10.1177/1203475418814234. [Epub ahead of print]

PMID:
30463416
10.

Psoriasis and cardiovascular disease: the elusive link.

Manolis AS, Manolis TA, Melita H, Manolis AS.

Int Rev Immunol. 2018 Nov 20:1-22. doi: 10.1080/08830185.2018.1539084. [Epub ahead of print]

PMID:
30457023
11.

Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.

Georgakopoulos JR, Phung M, Ighani A, Yeung J.

J Cutan Med Surg. 2018 Nov 18:1203475418814229. doi: 10.1177/1203475418814229. [Epub ahead of print]

PMID:
30449146
12.

JAK-inhibitors in dermatology. Current evidence and future applications.

Ciechanowicz P, Rakowska A, Sikora M, Rudnicka L.

J Dermatolog Treat. 2018 Nov 15:1-22. doi: 10.1080/09546634.2018.1546043. [Epub ahead of print]

PMID:
30433838
13.

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA.

Am J Clin Dermatol. 2018 Nov 12. doi: 10.1007/s40257-018-0396-z. [Epub ahead of print]

PMID:
30417277
14.

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.

Yosipovitch G, Foley P, Ryan C, Cather JC, Meeuwis KA, Burge R, Bleakman AP, Lin CY, Malatestinic W, Gottlieb A.

J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004.

15.

Efficacy and safety of pioglitazone plus phototherapy vs. phototherapy in patients with plaque type psoriasis: a double blinded randomized controlled trial.

Ghiasi M, Ebrahimi S, Lajevardi V, Taraz M, Azizpour A.

J Dermatolog Treat. 2018 Nov 3:1-15. doi: 10.1080/09546634.2018.1544702. [Epub ahead of print]

PMID:
30394148
16.

Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.

Elmamoun M, Leung YY, O'Sullivan D, Steinkoenig I, Chandran V, Gladman DD, FitzGerald OM, Orbai AM, Eder L.

J Rheumatol. 2018 Nov 1. pii: jrheum.180195. doi: 10.3899/jrheum.180195. [Epub ahead of print]

PMID:
30385708
17.

An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup.

Christenson SA, van den Berge M, Faiz A, Inkamp K, Bhakta N, Bonser LR, Zlock LT, Barjaktarevic IZ, Barr RG, Bleecker ER, Boucher RC, Bowler RP, Comellas AP, Curtis JL, Han MK, Hansel NN, Hiemstra PS, Kaner RJ, Krishnanm JA, Martinez FJ, O'Neal WK, Paine R 3rd, Timens W, Wells JM, Spira A, Erle DJ, Woodruff PG.

J Clin Invest. 2018 Nov 26. pii: 121087. doi: 10.1172/JCI121087. [Epub ahead of print]

18.

Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.

Reich K, Sullivan J, Arenberger P, Mrowietz U, Jazayeri S, Augustin M, Parneix A, Regnault P, You R, Milutinovic M.

Br J Dermatol. 2018 Oct 26. doi: 10.1111/bjd.17351. [Epub ahead of print]

PMID:
30367462
19.

Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.

Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH.

J Drugs Dermatol. 2018 Oct 1;17(10):1078-1082.

PMID:
30365588
20.

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069.

PMID:
30365586

Supplemental Content

Loading ...
Support Center